The United Arab Emirates (UAE), the Kingdom of Bahrain, Kuwait, Oman, and Qatar haveauthorised sotrovimab for emergency use. Local experience among physicians include recentsuccessful COVID-19 vaccine pivotal studies supported by the authorities' willingness toexpedite understanding of the role of monoclonal antibodies such as sotrovimab in themanagement of COVID-19 and expertise to integrate the latest knowledge into the local orregional COVID-19 management guidelines. The aim of this study is to collect localclinical evidence for sotrovimab effect in the real-life setting in the UAE and theKingdom of Bahrain. Overall study population is 20,000 and the duration of the study willbe approximately six months from recruitment date.
Not Provided
Drug: Sotrovimab
collect local clinical evidence for sotrovimab effect in the real-life setting
Inclusion Criteria:
- Adults and paediatric patients (≥ 12 years of age weighing at least 40 kg)
- Mild-to-moderate COVID-19
- Positive results of direct SARS-CoV-2 viral testing
- High risk for progression to severe COVID-19
Exclusion Criteria:
- Patients who are hospitalised due to COVID-19 before sotrovimab administration
- Patients who require oxygen therapy due to COVID-19 before sotrovimab administration
oPatients who received pharmacological treatment including monoclonal antibodies to
any components of SARS-CoV-2 virus within 6 months prior to enrolment into the study
in retrospective and prospective arms.
The National Taskforce for combating COVID-19, Royal Medical Services.
Manama, Bahrain
Investigator: Manaf Al Qahtani, MD
Nawal Al Kaabi, MD
+97124102985
research@seha.ae
Not Provided